<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <meta name="description" content="Guide to naproxen for pain and inflammation - a longer-acting NSAID for arthritis, injuries, and chronic pain.">
    <meta name="keywords" content="naproxen, Aleve, Naprosyn, NSAID, anti-inflammatory, arthritis medication">
    <title>Naproxen | ChronicSoreness</title>
    <link rel="stylesheet" href="../css/styles.css">
</head>
<body>
    <header class="header"><nav class="nav-container"><div class="logo"><a href="../index.html"><span class="logo-icon">ðŸ’œ</span><span class="logo-text"><strong>Chronic</strong>Soreness</span></a></div><button class="mobile-menu-toggle" aria-label="Toggle menu"><span class="hamburger"></span></button><ul class="nav-menu"><li><a href="../conditions.html">Conditions</a></li><li><a href="../treatments.html">Treatments</a></li><li><a href="../medications.html">Medications</a></li><li><a href="../exercise.html">Exercise</a></li><li><a href="../nutrition.html">Nutrition</a></li><li><a href="../mental-health.html">Mental Health</a></li></ul></nav></header>
    <main id="main-content">
        <article class="page-header"><h1>Naproxen</h1><p>Longer-acting anti-inflammatory relief</p></article>
        <section class="content-section">
            <div class="container">
                <h2>What Is Naproxen?</h2>
                <p>Naproxen is a nonsteroidal anti-inflammatory drug (NSAID) with a longer duration of action than ibuprofen, allowing for twice-daily dosing. It's effective for arthritis, menstrual pain, and various musculoskeletal conditions.<sup>1</sup></p>

                <h2>Brand Names</h2>
                <ul>
                    <li>Aleve (OTC)</li>
                    <li>Naprosyn (Rx)</li>
                    <li>Anaprox</li>
                    <li>Naprelan (extended-release)</li>
                </ul>

                <h2>Uses</h2>
                <ul>
                    <li>Osteoarthritis</li>
                    <li>Rheumatoid arthritis</li>
                    <li>Ankylosing spondylitis</li>
                    <li>Tendinitis and bursitis</li>
                    <li>Menstrual cramps</li>
                    <li>Gout attacks</li>
                    <li>Migraine</li>
                </ul>

                <h2>Dosing<sup>2</sup></h2>
                <ul>
                    <li><strong>OTC (Aleve)</strong> - 220 mg every 8-12 hours</li>
                    <li><strong>OTC maximum</strong> - 660 mg per day</li>
                    <li><strong>Prescription</strong> - 250-500 mg twice daily</li>
                    <li><strong>Prescription max</strong> - 1,250 mg first day, then 1,000 mg</li>
                </ul>

                <h2>Advantages</h2>
                <ul>
                    <li>Longer lasting (12 hours)</li>
                    <li>Twice-daily dosing</li>
                    <li>May have slightly lower cardiovascular risk than some NSAIDs</li>
                </ul>

                <h2>Risks<sup>3</sup></h2>
                <ul>
                    <li>Same NSAID risks as ibuprofen</li>
                    <li>GI bleeding and ulcers</li>
                    <li>Cardiovascular risks</li>
                    <li>Kidney effects</li>
                    <li>Higher risk with longer-term use</li>
                </ul>

                <h2>Who Should Avoid</h2>
                <ul>
                    <li>Prior GI bleeding</li>
                    <li>Kidney disease</li>
                    <li>Cardiovascular disease</li>
                    <li>Late pregnancy</li>
                    <li>On blood thinners</li>
                </ul>

                <h2>References</h2>
                <ol>
                    <li>Segre EJ. Naproxen sodium (Anaprox): pharmacology, pharmacokinetics and drug interactions. <em>J Reprod Med</em>. 1980;25(4 Suppl):222-225.</li>
                    <li>Todd PA, Clissold SP. Naproxen. A reappraisal of its pharmacology, and therapeutic use in rheumatic diseases and pain states. <em>Drugs</em>. 1990;40(1):91-137.</li>
                    <li>McGettigan P, Henry D. Cardiovascular risk with non-steroidal anti-inflammatory drugs. <em>PLoS Med</em>. 2011;8(9):e1001098.</li>
                </ol>
            </div>
        </section>
    </main>
    <footer class="footer"><div class="container"><p class="disclaimer">The information provided is for educational purposes only and is not medical advice.</p><p class="copyright">Â© 2024 ChronicSoreness. All rights reserved.</p></div></footer>
    <script src="../js/main.js"></script>
</body>
</html>
